Results of Association of 18F-FDG PET/CT Variables with PLC
| Variable | OR | P | ROC area | Cutoff | Se | Sp | LR+ | LR− |
| PET qualitative (peritumoral increased uptake) | 85.31 (19.6–371) | <0.001 | 0.89 (0.81–0.97) | — | 0.94 (0.86–0.98) | 0.84 (0.64–0.96) | 5.89 (2.39–14.5) | 0.07 (0.03–0.18) |
| PET quantitative | ||||||||
| Tumor SUVmax (g/mL) | 1.10 (1.02–1.18) | 0.011 | 0.70 (0.58–0.83) | 9.1 | 0.74 (0.62–0.84) | 0.64 (0.43–0.82) | 2.05 (1.2–3.53) | 0.41 (0.25–0.67) |
| Tumor SUVmean (g/mL) | 1.15 (1.02–1.29) | 0.019 | 0.70 (0.57–0.82) | 5.5 | 0.73 (0.60–0.83) | 0.64 (0.43–0.82) | 2.01 (1.17–3.46) | 0.43 (0.27–0.70) |
| MTV (cm3) | 1.06 (1.00–1.11) | 0.022 | 0.70 (0.58–0.82) | 11.3 | 0.55 (0.43–0.67) | 0.76 (0.55–0.91) | 2.29 (1.11–4.76) | 0.59 (0.42–0.83) |
| TLG (g⋅cm3/mL) | 1.00 (1.00–1.01) | 0.027 | 0.73 (0.61–0.85) | 14.6 | 0.90 (0.80–0.96) | 0.52 (0.31–0.72) | 1.87 (1.24–2.84) | 0.20 (0.09–0.43) |
| Peritumoral SUVmax (g/mL) | 312 (13.7–7124) | <0.001 | 0.98 (0.96–1.00) | 2.1 | 0.97 (0.90–1.00) | 0.92 (0.74–0.99) | 12.14 (3.21–45.9) | 0.03 (0.01–0.12) |
| Peritumoral SUVmean (g/mL) | 724 (41.70–12,593) | <0.001 | 0.96 (0.92–1.00) | 1.2 | 0.94 (0.86–0.98) | 0.88 (0.69–0.98) | 7.85 (2.71–22.7) | 0.07 (0.03–0.17) |
| Peritumoral SUVmax ratio | 63.0 (9.89–401) | <0.001 | 0.96 (0.92–1.00) | 2.3 | 0.93 (0.84–0.98) | 0.88 (0.69–0.98) | 7.73 (2.67–22.4) | 0.08 (0.04–0.19) |
| Peritumoral SUVmean ratio | 16.9 (5.24–54.5) | <0.001 | 0.92 (0.84–0.99) | 2.4 | 0.84 (0.73–0.92) | 0.92 (0.74–0.99) | 10.51 (2.77–39.9) | 0.17 (0.10–0.30) |
Se = sensitivity; Sp = specificity; LR+ = positive likelihood ratio; LR− = negative likelihood ratio; MTV = metabolic tumor volume, TLG = total lesion glycolysis.
Data in parentheses are 95%CI. P < 0.003 was considered statistically significant to account for multiple testing. Cutoffs were determined by Liu method.